Fewer than a tenth of people who could benefit from obesity jabs like Wegovy can access them, caution the World Health Organization as it releases its initial guidance on the therapies.
With in excess of 1,000,000,000 people worldwide now living with obesity, it is urging increased and just access to GLP-1 medication.
Per projections, more than two billion will be obese by 2030 without intervention.
"The latest guidelines affirms that obesity is a long-term condition that can be managed with thorough and continuous treatment," remarked WHO director-general Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and logistical bottlenecks are significant obstacles to universal access to the treatments that can aid individuals in losing substantial weight, says the organization.
Skinny Jab Supply Crisis
Despite the current best projected outlook, the production of these medications might only reach approximately 100 million people – under 10% of eligible patients, according to the health organization.
The guideline urges countries and companies to expand access, through measures such as licensing agreements.
Exclusive production rights on a key compound – the main component of a leading brand – is due to expire in a number of countries in 2026.
How Obesity Injections Work
These medications mimick a biological compound to reduce digestion speed, suppress the appetite and increase feelings of fullness so people reduce food intake.
Individuals commonly see weight reduction after several weeks of starting on the weekly injections.
Evidence indicates patients may put most of the weight back on a year later of stopping the drug, when their normal hunger return.
Being above a healthy weight raises your likelihood for contracting diseases, like diabetes, cardiovascular issues, stroke, and specific malignancies.
Excess weight affects individuals in countries worldwide and was responsible for 3.7 million fatalities worldwide in 2024, according to the health agency.
